Research About Meet PRIA

Support Data Sources Privacy Policy Terms of Service Your Privacy Choiceshello@policyrisk.com

© 2026 PRIA Technologies, LLC. All rights reserved.

PRIA provides educational policy intelligence and is not a source of investment, legal, or financial advice. Content is for informational purposes only.

™

Your Policy Risk Impact Agent

Research

At My Address
Federal Courts
Daily Briefings
Medicare & Social Security
Congressional Bills
Federal Register
Tariffs
Fed Decisions & The Economy
State Tracker
World Watch
U.S. Code
U.S. Constitution

Knowledge

Search Polipedia
Daily Briefings
Calculators
What is Policy Risk?
The Countdown

Company

About PRIA
Support

Get PRIA

Support Data Sources Privacy Policy Terms of Service Your Privacy Choices

hello@policyrisk.com

© 2026 PRIA Technologies, LLC. All rights reserved.

PRIA is a trademark of PRIA Technologies, LLC.

PRIA provides educational policy intelligence and is not a source of investment, legal, or financial advice. Content is for informational purposes only.

Colorado Statutes, Title 25

™

Your Policy Risk Impact Agent

Colorado/Statutes

← All Colorado coverage

Title 25, Public Health and Environment

0 chapters · 1,607 sections in this title.

All chapters in Title 251,607 Ch 4191 Ch 7166 Ch 5114 Ch 1587 Ch 186 Ch 3.586 Ch 884 Ch 1777 Ch 1.569 Ch 367 Ch 20.559 Ch 5.539 Ch 2531 Ch 230

15 sections·Filtered byTitle 25✕Ch 45✕

Colo. Rev. Stat. § 25-45-101 Short title
0.2K chars
This article shall be known and may be cited as the "Right to Try Act". Source: L. 2014: Entire article added, (HB 14-1281), ch. 220, p. 823, § 1, effective May 17.
Colo. Rev. Stat. § 25-45-102 Legislative declaration
1.6K chars
(1) For purposes of this part 1, the general assembly finds and declares that: (a) The process of approval for investigational drugs, biological products, and devices in the United States protects future patients from premature, ineffective, and unsafe medications and treatments …
Colo. Rev. Stat. § 25-45-103 Definitions
3.9K chars
As used in this part 1, unless the context otherwise requires: (1) (a) "Eligible patient" means a person who has: (I) A terminal illness, attested to by the patient's treating physician; (II) Considered all other treatment options currently approved by the United States food and …
Colo. Rev. Stat. § 25-45-104 Drug manufacturers - availability of investigational drugs, biological products, or devices - costs - insurance coverage
1.9K chars

(1) A manufacturer of an investigational drug, biological product, or device may make available the manufacturer's investigational drug, biological product, or device to eligible patients pursuant to this part 1. This part 1 does not require that a manufacturer make available an …

Colo. Rev. Stat. § 25-45-105 Action against health-care provider's license or medicare certification prohibited

0.8K chars

Notwithstanding any other law, a licensing board may not revoke, fail to renew, suspend, or take any action against a health-care provider's license issued pursuant to title 12, C.R.S., based solely on the health-care provider's recommendations to an eligible patient regarding ac…

Colo. Rev. Stat. § 25-45-106 Access to investigational drugs, biological products, and devices

0.4K chars

An official, employee, or agent of this state shall not block or attempt to block an eligible patient's access to an investigational drug, biological product, or device. Counseling, advice, or a recommendation consistent with medical standards of care from a licensed health-care …

Colo. Rev. Stat. § 25-45-107 No cause of action created

0.7K chars

This part 1 does not create a private cause of action against a manufacturer of an investigational drug, biological product, or device, or against any other person or entity involved in the care of an eligible patient using the investigational drug, biological product, or device,…

Colo. Rev. Stat. § 25-45-108 Effect on health-care coverage

0.2K chars

Nothing in this section affects the mandatory health-care coverage for participation in clinical trials pursuant to section 10-16-106 (20), C.R.S. Source: L. 2014: Entire article added, (HB 14-1281), ch. 220, p. 827, § 1, effective May 17.

Colo. Rev. Stat. § 25-45-201 Legislative declaration

1.3K chars

(1) For purposes of this part 2, the general assembly finds and determines that: (a) Some public and private entities operating under federal standards for the protection of human subjects in research develop individualized investigational drugs, biological products, and devices …

Colo. Rev. Stat. § 25-45-202 Definitions

4.8K chars

As used in this part 2, unless the context otherwise requires: (1) "Eligible facility" means an institution operating under the federalwide assurance for the protection of human subjects in accordance with 45 CFR 46 and 42 U.S.C. sec. 289a. (2) "Eligible patient" means an individ…

Colo. Rev. Stat. § 25-45-203 Drug manufacturers - authorized access to and use of individualized investigational drugs, biological products, or devices - costs

1.4K chars

(1) A manufacturer operating within an eligible facility and in accordance with applicable federal law may make available to an eligible patient, and an eligible patient may request, the manufacturer's individualized investigational drug, biological product, or device from the el…

Colo. Rev. Stat. § 25-45-204 Action against health-care provider's license or medicare certification prohibited

0.8K chars

Notwithstanding any other law, a licensing board shall not revoke, fail to renew, suspend, or take other action against a health-care provider's license issued pursuant to title 12 based solely on the health-care provider's recommendation to an eligible patient regarding access t…

Colo. Rev. Stat. § 25-45-205 Access to individualized investigational drugs, biological products, and devices - prohibition on state action

0.4K chars

An official, employee, or agent of this state shall not block or attempt to block an eligible patient's access to an individualized investigational drug, biological product, or device. Counseling, advice, or a recommendation consistent with medical standards of care from a licens…

Colo. Rev. Stat. § 25-45-206 No cause of action created

0.7K chars

This part 2 does not create a private right of action against a manufacturer of an individualized investigational drug, biological product, or device, or against an individual or entity involved in the care of an eligible patient using an individualized investigational drug, biol…

Colo. Rev. Stat. § 25-45-207 Effect on health-care coverage

0.3K chars

Nothing in this part 2 affects a health insurance provider's obligation to provide coverage for an insured's participation in a clinical trial pursuant to section 10-16-104 (20). Source: L. 2025: Entire part added, (HB 25-1270), ch. 211, p. 958, § 5, effective May 19.